

### Remarks

Claims 1-20 were pending in the application. Claims 8-20 were cancelled. Claims 21-25 were added. Therefore, claims 1-7 and 21-25 are now pending.

The specification was amended to indicate that the present application is a divisional application of an earlier-filed application.

Claims 2-5 were amended to remove the unnecessary phrase "selected from the group."  
Claims 6 and 7 were amended to remove the unnecessary term "respectively."

Support for the new claims can be found throughout the specification, for example:

Claim 21: page 6, lines 18-21;

Claim 22: page 6, lines 18-21; page 11, lines 30-31;

Claim 23: page 6, lines 18-21; page 8, lines 8-20;

Claim 24: page 8, lines 15 – page 10, line 4; and


Claim 25: page 15 line 11- page 16 line 33.

Therefore, no new matter is added by this amendment.

If there are any questions concerning this amendment, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446  
96941.doc

**Marked-up Version of Amended Claims and Specification  
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

**In the Specification:** Replace the paragraph on page 1, lines 16-18, with the following:

This patent application is a divisional application of U.S. Patent Application No. 09/454,753 filed December 6, 1999, which claims priority to U.S. Provisional Patent Application No. 60/111,334 filed December 7, 1998.

**In the claims:**

2. (Amended) The composition of Claim 1 wherein the polypeptide has a molecular weight [selected from the group] of approximately 33 kDa, 38 kDa, [and] or 42 kDa, as determined by SDS-PAGE analysis.

3. (Amended) The composition of Claim 1 wherein the polypeptide has a molecular weight [selected from the group] of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.

4. (Amended) The composition of Claim 1 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having a molecular weight [selected from the group] of approximately 33 kDa, 38 kDa, [and] or 42 kDa, as determined by SDS-PAGE analysis.

5. (Amended) The composition of Claim 1 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having a molecular weight [selected from the group] of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.

6. (Amended) The composition of Claim 1 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights

10072722 "020502"

of approximately 33 kDa, 38 kDa, and 42 kDa[, respectively], as determined by SDS-PAGE analysis.

7. (Amended) The composition of Claim 1 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, [or] and 42.1 kDa[, respectively], as determined by SDS-PAGE analysis.

8. (Cancel) [A method for detecting *T. solium* in a biological sample comprising combining the sample with a composition comprising an isolated, adult *Taenia solium* excretory/secretory polypeptide and detecting the binding of the polypeptide to an anti-polypeptide antibody in the sample.]

9. (Cancel) [The method of Claim 8 wherein the polypeptide has a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.]

10. (Cancel) [The method of Claim 8 wherein the polypeptide has a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.]

11. (Cancel) [The method of Claim 8 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having a molecular weight selected from the group of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.]

12. (Cancel) [The method of Claim 8 wherein the polypeptide is a mixture of two or more isolated, adult *Taenia solium* excretory/secretory polypeptides having a molecular weight selected from the group of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, as determined by SDS-PAGE analysis.]

10072722.020502

13. (Cancel) [The method of Claim 8 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 33 kDa, 38 kDa, and 42 kDa, respectively, as determined by SDS-PAGE analysis.]

14. (Cancel) [The method of Claim 8 wherein the polypeptide is a mixture of three isolated, adult *Taenia solium* excretory/secretory polypeptides having molecular weights of approximately 32.7 kDa, 37.8 kDa, or 42.1 kDa, respectively, as determined by SDS-PAGE analysis.]

15. (Cancel) [The method of Claim 8 wherein the binding is detected by immunoassay.]

16. (Cancel) [The method of Claim 15 wherein the immunoassay is an immunoblot assay.]

17. (Cancel) [The method of Claim 8 wherein the biological sample is a biological fluid.]

18. (Cancel) [The method of Claim 8 wherein the biological sample is a biological fluid selected from the group consisting of blood serum, blood plasma and saliva.]

19. (Cancel) [A method for diagnosing taeniasis in a human comprising contacting a biological sample of the human with an adult *Taenia solium* excretory/secretory polypeptide and detecting the binding of antibody present in the biological sample to the polypeptide, wherein the detection of binding indicates taeniasis.]

20. (Cancel) [The method of Claim 19 wherein the polypeptide has a molecular weight selected from the group consisting of approximately 33 kDa, 38 kDa, and 42 kDa, as determined by SDS-PAGE analysis.]

100733-020502

21. (New) The composition of claim 1, wherein the polypeptide is immobilized.
22. (New) The composition of claim 21, wherein the polypeptide is immobilized to a solid phase bead or particle.
23. (New) The composition of claim 1, wherein the polypeptide comprises a label.
24. (New) The composition of claim 23, wherein the label is a fluorescent molecule, a luminescent molecule, a radiolabel, a chromogenic substance, or an enzyme.
25. (New) A kit comprising the composition of claim 1.

205020-262200T